Welcome to Napo EU

Our Story

Napo EU S.p.A. is the recently incorporated subsidiary of Jaguar Health, Inc. in Milan, Italy.

The company will be responsible for bringing crofelemer products from Jaguar Health’s wholly-owned subsidiary Napo Pharmaceuticals, Inc. (“Napo”) to the European market.

Napo is a commercial stage pharmaceutical company based in San Francisco, CA that is focused on developing novel, plant-based, sustainably derived prescription medicines for people with gastrointestinal distress, specifically chronic, debilitating diarrhea. Napo markets proprietary plant-based pharmaceuticals harvested responsibly from rainforest areas.

Napo’s lead product – Mytesi® (crofelemer 125 mg delayed-release tablets) – is approved by the US Food and Drug Administration for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and is the only oral botanical prescription medicine approved in the US under FDA Botanical Guidance.

Napo plans to study crofelemer in the EU for both symptomatic and prophylactic relief from inflammatory diarrhea in the ‘long-hauler’ COVID-19 recovery patient population. Napo EU also intends to develop crofelemer for additional indications in Europe, including HIV-related diarrhea, cancer therapy-related diarrhea (currently being evaluated in a pivotal Phase 3 clinical trial in the US), and potentially other follow-on indications.

For more information, please contact hello@jaguar.health

Indication
MYTESI® is an antidiarrheal indicated in the US for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).

Important Safety Information about MYTESI®
MYTESI® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting MYTESI®.

If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

Click to Read Full Prescribing Information